Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Chief Development Officer | February 28, 2022 | March 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Crinetics Pharmaceuticals, Inc.
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,995 |
Reported balance
After 2022-02-28 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-02-28 · Grant · Acquired 13,950 · Balance 185,995 F1: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 176,995 |
Reported balance
After 2022-03-01 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-03-01 · Sale · Acquired 9,000 · Balance 176,995 F2: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. |
| Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2032-02-27 | Direct | 65,400 |
Reported balance
After 2022-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-28 · Grant · Acquired 65,400 · Balance 65,400 F3: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.
F2: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F3: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 2, 2022 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 9,000 | $19.88 | $178,920.00 |
DisclosureSEC source: 0001209191-22-015131 · doc4.xml · nonDerivative · entry 2 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,995 F2 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock (right to buy) · Derivative | 65,400 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0001209191-22-015131 · doc4.xml · derivative · entry 3 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,400 Underlying: Common Stock · 65,400 shares Expires 2032-02-27 F3 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 13,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015131 · doc4.xml · nonDerivative · entry 1 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,995 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 17:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 13,411 | $17.83 | $239,084.60 |
DisclosureSEC source: 0001209191-22-008061 · doc4.xml · nonDerivative · entry 1 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,045 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $17.170 and $18.015. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| November 19, 2021 Filed Feb 4, 2022 16:26 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 785 | $11.02 | $8,650.70 |
DisclosureSEC source: 0001209191-22-007198 · doc5.xml · nonDerivative · entry 1 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,456 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 19:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (right to buy) · Derivative | 106,383 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-21-062263 · doc4.xml · derivative · entry 2 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,383 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on July 17, 2017 and 1/48th of the total remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 19:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 106,383 | $0.73 | $77,659.59 |
DisclosureSEC source: 0001209191-21-062263 · doc4.xml · nonDerivative · entry 1 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 772 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:25 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 131,000 | $0.00 Strike: $15.29 | $0.00 |
DisclosureSEC source: 0001209191-21-016278 · doc4.xml · derivative · entry 1 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021. Read SEC document |
| May 20, 2020 Filed Feb 5, 2021 16:48 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,470 | $14.45 | $21,241.50 |
DisclosureSEC source: 0001209191-21-008120 · doc5.xml · nonDerivative · entry 1 Madan Ajay · CIK 0001807856 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,516 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.